EDN FUMIGANT Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

edn fumigant

draslovka services pty ltd - ethanedinitrile - pressurised gas - ethanedinitrile gas active 1000.0 g/kg - mixed function pesticide - felled log, post and pole | timber | log | pole | post | wood - insect pest of timber | wood fungus | borers | lyctids | quarantine timber insects | termite | timber destroying insects | wood decaying fungi | wood rot | wood rotting fungi | wood staining fungi | wood-destroying fungi

VAXSAFE HVT VACCINE (LIVING) Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vaxsafe hvt vaccine (living)

bioproperties pty. ltd. - herpes virus of turkeys (hvt) strain fc 126 - misc. vaccines or anti sera - herpes virus of turkeys (hvt) strain fc 126 vaccine-viral active 4000.0 pfu/dose - immunotherapy - embryonated chicken egg | poultry chicks | chickens | day old chicks | hatchlings - marek's disease | herpes virus of turkeys (hvt)

VAXSAFE RIS VACCINE (LIVING) Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vaxsafe ris vaccine (living)

bioproperties pty. ltd. - marek's disease - misc. vaccines or anti sera - marek's disease vaccine-general active 0.0 p - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - vaccine | equine rotavirus

TERRAMYCIN PINKEYE AEROSOL Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

terramycin pinkeye aerosol

zoetis australia pty ltd - oxytetracycline hydrochloride - topical aerosol spray - oxytetracycline hydrochloride antibiotic active 2.0 mg/g - ophthalmic preparations - animal | cattle | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | h - anti-infective or antiseptic | bacterial infections | conjunctivitis | eye infections | eye-washes | keratoconjunctivitis | ocular infections

BUSULFAN ACCORD busulfan 60 mg/10 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

busulfan accord busulfan 60 mg/10 ml concentrated injection vial

accord healthcare pty ltd - busulfan, quantity: 60 mg - injection, concentrated - excipient ingredients: macrogol 400; dimethylacetamide - busulfan accord is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

DOPAMINE JUNO dopamine hydrochloride 200 mg/5 mL concentrated injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

dopamine juno dopamine hydrochloride 200 mg/5 ml concentrated injection ampoules

juno pharmaceuticals pty ltd - dopamine hydrochloride, quantity: 200 mg - injection, concentrated - excipient ingredients: sodium chloride; potassium metabisulfite; water for injections; hydrochloric acid; sodium hydroxide - for the correction of haemodynamic imbalance present in: acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure. as an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia. in chronic cardiac decompensation as in congestive failure.

THIOTEPA-REACH thiotepa 100 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

thiotepa-reach thiotepa 100 mg powder for injection vial

reach pharmaceuticals pty ltd - thiotepa, quantity: 100 mg - injection, powder for - excipient ingredients: - thiotepa-reach is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. (refer to section 5.2 clinical trials)